AUS
NZ
UK
CA
USA
IND
The below mentioned healthcare stocks have made strong strategic progress in the recent past. There these stocks are currently on investors' radar. Letâs take a closer look at these stocks-
Nuheara Limited (ASX:NUH)
Innovative audio wearables company, Nuheara Limited (ASX: NUH) creates game-changing hearing solutions for global hearing market. The company has already achieved success with its revolutionary wireless earbuds, IQbudsTM which are sold in major consumer electronics retailers. Now the companyâs other revolutionary product IQstream TV⢠is also available for purchase at the companyâs website (www.nuheara.com). After receiving all necessary certifications for its IQstream TVâ¢, the company has made this product available for global hearing market. In its quest for providing Smart Hearing products to enable consumers to obtain affordable and accessible hearing solutions, the company has announced a series of new products, accessories and retail support tools during the March quarter. As the company has made significant progress in the recent past, many investors are keeping an eye on this stock.
In the last six months, the share price of the company increased substantially by 33.90% as on 16 May 2019. On 17 May 2019, NUHâs shares closed the trading at a price of $0.070 down by 11.392% with a market capitalization of circa $77.59 million.
Neuren Pharmaceuticals Limited (ASX:NEU)
Biopharmaceutical company, Neuren Pharmaceuticals Limited (ASX: NEU) recently validated product pipeline for NNZ-2591 in neurodevelopmental disorders. In announcements made on 17 May 2019, the company informed that its drug candidate NNZ-2591 has normalized all deficits in a pre-clinical model of Angelman syndrome (AS) and neurodevelopmental disorder Pitt Hopkins syndrome, confirming the potential of this unique neurotrophic drug across a number of neurodegenerative and neurodevelopmental conditions.
The company is now accelerating the remaining tasks including the manufacturing development, toxicity studies and a Phase 1 clinical study that are required before commencing Phase 2 clinical studies with NNZ2591.
In the last six months, the share price of the company decreased by 31.33% as on 16 May 2019. On 17 May 2019, NEUâs shares closed the trading at a price of $1.180 up by 14.563% with a market capitalization of circa $105.75 million.
Rhinomed Limited (ASX:RNO)
Rhinomed Limited (ASX: RNO) a leader in nasal respiratory technology, has confirmed that itâs revolutionary new Pronto⢠rechargeable, dual action, vapour release technology has been registered with both the US FDA and the Australian TGA as a class I medical device. In Australia, the company can confirm the classification of Pronto as a Class I medical device and in the USA, the company has now completed registration of Pronto covering both variants - Pronto Sleep and Pronto Clear - as a Class I medical device with the US FDA.
Pronto Sleep and Pronto Clear (Source: Company Reports)
By combining this new technology with the Muteâs stenting action, the company is able to provide a unique dual action device. This new device not only improves nasal airflow but also delivers a soothing blend of pure essential oils traditionally known to help clear a stuffy nose or to help in getting better sleep.
In the last six months, the share price of the company decreased by 2.33% as on 16 May 2019. On 17 May 2019, RNOâs shares closed the trading at a price of $0.210 with a market capitalization of circa $29.81 million.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.